What to Know About Reglan and Tardive Dyskinesia in Virginia
From General Health Awareness to Specific Legal Concerns
If you or a loved one developed uncontrollable facial or body movements after taking Reglan, you may be experiencing tardive dyskinesia. This condition is a known risk of long-term metoclopramide use, yet many patients are not warned. The medical community has long recognized the importance of informed consent and risk communication, a principle that guides our discussion here. This page covers the key facts about Reglan and tardive dyskinesia, including symptoms, FDA warnings, and what Virginia residents should know.
Understanding Reglan and Its Approved Uses
Reglan (metoclopramide) is a prescription medication approved for short-term treatment of symptomatic gastroesophageal reflux in adults who have not responded to conventional therapy, and for relief of symptoms in adults with acute and recurrent diabetic gastroparesis (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). The drug carries a boxed warning stating that metoclopramide, including Reglan, can cause tardive dyskinesia (TD), a potentially irreversible serious movement disorder (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). TD is characterized by involuntary, repetitive movements of the face, tongue, trunk, and extremities, and may be disfiguring (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). The risk of developing TD increases with the duration of metoclopramide treatment and total cumulative dosage (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). For patients with symptomatic gastroesophageal reflux, the maximum approved treatment duration is 12 weeks (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). In patients with diabetic gastroparesis, treatment should not exceed 12 weeks; if longer use is unavoidable, routine monitoring for signs and symptoms of TD is recommended (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). Reglan is contraindicated in patients with a history of TD, and the drug should be immediately discontinued if signs or symptoms of TD develop (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). Additionally, Reglan is not recommended for use in pediatric patients due to the risk of TD and other extrapyramidal symptoms (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397).
Mechanism of Tardive Dyskinesia and Risk Factors
The mechanistic link between Reglan and TD involves metoclopramide's action as a dopamine receptor antagonist in the central nervous system. Chronic blockade of dopamine D2 receptors in the basal ganglia can lead to upregulation of these receptors and subsequent hypersensitivity, which is thought to underlie the development of involuntary movements. The drug may also suppress or partially suppress the signs of TD, potentially delaying diagnosis by masking the underlying disease process (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). For patients in Virginia who have developed TD after taking Reglan, several legal considerations arise. The statute of limitations for personal injury claims in Virginia is generally two years from the date the injury is discovered or reasonably should have been discovered. Given that TD can develop insidiously and may be masked by continued use of metoclopramide, the timeline between exposure and documented harm is critical. Patients may not recognize symptoms—such as lip smacking, tongue protrusion, or facial grimacing—until after the drug is discontinued, as the drug can suppress these movements. The boxed warning emphasizes that Reglan should be used for the shortest duration possible and that the need for continued treatment should be periodically reassessed (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). However, many patients have been prescribed Reglan for extended periods, sometimes years, without adequate monitoring.
Legal Considerations for Virginia Patients
Adequacy of warnings is a central issue in potential litigation. The FDA-mandated boxed warning clearly states the risk of TD and the importance of limiting treatment duration. However, patients and healthcare providers may not have received or understood these warnings, particularly if the drug was prescribed off-label or for longer than recommended. The warning also notes that Reglan is contraindicated in patients with a history of TD, but a history may not be documented if symptoms were mild or misattributed. For attorneys representing affected patients, key considerations include documenting the duration and dosage of Reglan use, the onset and progression of TD symptoms, and whether the prescribing physician provided adequate information about risks. Medical records, pharmacy records, and expert testimony on the clinical presentation of TD are essential. In Virginia, the statute of limitations may be affected by the discovery rule, which allows the clock to start when the injury is discovered. Given that TD can be irreversible and may not be immediately recognized, patients should seek legal advice promptly upon diagnosis. The timeline between exposure and harm can be years, but the law requires timely action once the connection is known. Patients should also be aware that the boxed warning explicitly states that Reglan can cause TD and that the drug should be discontinued immediately if symptoms appear (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). Failure to do so may be considered a deviation from standard of care.
Summary and Next Steps
In summary, Reglan use carries a well-documented risk of TD, with the risk increasing with longer treatment duration and higher cumulative doses. The drug's labeling includes a boxed warning and specific usage limitations, but patients may still develop TD due to prolonged use or inadequate monitoring. For Virginia residents, the statute of limitations for filing a claim is typically two years from discovery of the injury, making timely legal consultation important. Attorneys should focus on the duration of Reglan therapy, the adequacy of warnings provided, and the clinical timeline of TD onset. References https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397
Important Notice
This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.
Frequently Asked Questions
What is the statute of limitations for Reglan-related tardive dyskinesia claims in Virginia?
In Virginia, the statute of limitations for personal injury claims is generally two years from the date the injury is discovered or reasonably should have been discovered. For tardive dyskinesia caused by Reglan, this means the clock starts when you become aware of the connection between your symptoms and the medication. It is crucial to seek legal advice promptly after diagnosis.
Can tardive dyskinesia from Reglan be reversed?
Tardive dyskinesia is often irreversible, especially if the medication is not discontinued promptly. The boxed warning for Reglan states that the drug can cause potentially irreversible TD. Early detection and discontinuation of Reglan may improve outcomes, but some symptoms may persist even after stopping the drug.
Does submitting information create an attorney-client relationship?
No. Submission requests an initial records screening only and does not create an attorney-client relationship.
Related Articles
References
Request a Free Case Review
This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.